Table 3 Description of the most relevant TEAEs.

The table includes TEAEs that were observed in three (19%) or more patients from BO-112 monotherapy cohorts 1 to 3 and in three (10%) or more patients from cohort 4, BO-112 combined with anti–PD-1.

Adverse event
(preferred
term)
All TEAEs
n (%)
TEAEs related to BO-112
n (%)
AllGrades 3–5AllGrades 3–5
Cohorts 1–3Cohort 4Cohorts 1–3Cohort 4Cohorts 1–3Cohort 4Cohorts 1–3Cohort 4
n = 16n = 28n = 16n = 28n = 16n = 28n = 16n = 28
Anemia2 (12.5)5 (17.9)1 (6.3)1 (3.6)0000
Abdominal pain1 (6.3)7 (25.0)1 (6.3)1 (3.6)0000
Constipation2 (12.5)6 (21.4)1 (6.3)00000
Diarrhea08 (28.6)01 (3.6)0000
Dry mouth2 (12.5)4 (14.3)0002 (16.7)00
Nausea4 (25.0)13 (46.4)001 (6.3)7 (25.0)00
Vomiting2 (12.5)7 (25.0)001 (6.3)4 (14.3)00
Asthenia4 (25.0)16 (57.1)1 (6.3)009 (32.1)00
Chills2 (12.5)7 (25.0)002 (12.5)6 (21.4)00
Fatigue3 (18.8)3 (10.7)002 (7.1)0
Injection site pain1 (6.3)5 (17.9)001 (6.3)3 (10.7)00
Pain2 (12.5)6 (21.4)01 (3.6)0000
Pyrexia4 (25.0)21 (75.0)003 (18.8)18 (64.3)00
Respiratory tract infection2 (12.5)4 (14.3)02 (7.1)0000
Decreased appetite1 (6.3)9 (32.1)0004 (14.3)00
Back pain2 (12.5)5 (17.9)1 (6.3)1 (3.6)0000
Musculoskeletal pain04 (14.3)01 (3.6)01 (3.6)00
Myalgia2 (12.5)7(25.0)001 (6.3)6 (21.4)00
Neck pain03 (10.7)000000
Tumor pain03 (10.7)01 (3.6)0000
Dizziness1 (6.3)5 (17.9)0002 (7.1)00
Dysgeusia04 (14.3)0002 (7.1)00
Headache3 (18.8)6 (21.4)002 (12.5)1 (3.6)00
Syncope04 (14.3)02 (7.1)0000
Anxiety05 (17.9)000000
Insomnia1 (6.3)4 (14.3)000000
Cough04 (14.3)000000
Dyspnea05 (17.9)000000
Productive cough06 (21.4)000000
Respiratory disorder04 (14.3)000000
Pruritus06 (21.4)0003 (10.7)00